SEATTLE – October 05, 2026 -- Mozart Therapeutics presented three new data sets on its lead candidate MTX-101 at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD), held September 28–October 2, 2026, in Milan, Italy, advancing the bispecific antibody toward a planned Phase 2a trial in Stage 3 type 1 diabetes with enrollment targeted for the first half of 2027.

San Rafael, Calif. – October 05, 2026 -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) appointed Cara Bauer, Ph.D., as Executive Vice President, Chief People Officer, effective Oct. 5, 2026, succeeding Amy Wireman, who is retiring after nearly 14 years at the company.

North Chicago / Copenhagen – October 05, 2026 -- AbbVie and Genmab A/S reported that epcoritamab combined with standard R-CHOP chemotherapy reduced the risk of disease progression or death by 51% versus R-CHOP alone in newly diagnosed diffuse large B-cell lymphoma (DLBCL) patients, based on topline Phase 3 data.

Ahmedabad – – October 05, 2026 -- Zydus Lifesciences Limited, in partnership with MSN Laboratories Private Limited, has launched the first generic version of riociguat in the United States, undercutting a branded drug whose maker, Bayer, reported approximately EUR 745 million (roughly USD 850 million) in global sales for 2025.

Delray Beach, Fla. – October 05, 2026 -- The global AI in Protein Engineering market will climb to USD 3.82 billion by 2031 from USD 1.44 billion in 2026, a 21.6% compound annual growth rate, according to a new forecast from MarketsandMarkets.

New York – October 05, 2026 -- A new multisector coalition launched the 30x30x50 Brain Challenge, pledging to cut stroke incidence by 30 percent and increase primary-care cognitive screening by 50 percent across 30 global cities by 2031.

San Carlos, Calif. – October 05, 2026 -- A non-invasive urine test can now predict whether bladder cancer patients will respond to immunotherapy before treatment even begins, according to a Stanford-led study published in Nature Medicine and announced by Resero Bio.

Bridgewater, N.J. – – October 05, 2026 -- Insmed Incorporated (Nasdaq: INSM) announced that Chief Financial Officer Sara Bonstein will step down on October 30, 2026, after nearly seven years in the role, during which the company raised more than $4.2 billion in capital.

Taipei, Shanghai and San Francisco – October 05, 2026 -- HanchorBio, Inc. (TWSE: 7827) said the U.S. Food and Drug Administration has cleared the investigational new drug application for HCB303, clearing the path for the company's second trispecific immunotherapy to enter human testing.

Taipei – October 05, 2026 -- Energenesis Biomedical Co., Ltd. (TWSE: 6657) has signed a Memorandum of Understanding with South Korea's Yoo Young Pharm. Co., Ltd. (YYP) to pursue development, registration, and commercialization of its diabetic foot ulcer drug candidate ENERGI-F703DFU in the Korean market.